American Diabetes Association (ADA) 2026 Scientific Sessions
- Start Date:
05 Jun 2026
- End Date:
08 Jun 2026
- Location:
New Orleans, LA
- Region:
N. America
- Booth #:
1302
Thermo Fisher Scientific is proud to be an exhibitor at the 2026 ADA Scientific Sessions
Bringing drugs to market for metabolic disorders — including diabetes, obesity and related diseases — comes with a unique set of challenges. As prevalence of these diseases grows, patients worldwide are left to manage significant health issues. Without advancements in treatments for these diseases and related comorbidities, both patients and health care systems face a substantial burden. To accelerate much-needed metabolic drug development, sponsors turn to the PPD™ clinical research business of Thermo Fisher Scientific.
Our experience and expertise in planning, advancing and delivering Phase I-IV metabolic clinical trials across a broad range of drug classes enables drug developers to overcome challenges and bring much-needed treatments to affected patients.
Our expertise spans the full spectrum of metabolic and endocrine diseases
- Cardiovascular disease
- Chronic and diabetic kidney disease (CKD and DKD)
- Diabetes (Type 1 and Type 2)
- Heart failure
- Hypercholesterolemia and hypertriglyceridemia
- Inborn errors of metabolism (IEM)
- Metabolic dysfunction-associated steatohepatitis (MASH)
- Metabolic dysfunction-associated steatotic liver disease (MASLD)
- Obesity
Novel targeted approaches, including cell and gene therapies, are emerging as treatment paradigms change for metabolic disorders. To enable sponsors to successfully navigate this evolving landscape, we offer end-to-end clinical trial solutions across indications that incorporate strategies for clinical development, patient recruitment and retention, site engagement, project management, and regulatory strategies.
By partnering with an experienced provider of clinical research solutions for metabolic and clinical trials, you are better positioned to drive your treatments forward and meet key milestones, faster.